Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
Newsletters
Training
White Papers
Advertising
Contact Us
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > Spain Approves Cannabis Drug for MS

FDAnews Drug Daily Bulletin

July 29, 2010 | Vol. 7 No. 147

Spain Approves Cannabis Drug for MS

GW Pharmaceuticals’ cannabis-derived medicine Sativex has been approved in its second European market, Spain, as an add-on therapy for treating spasticity in patients with multiple sclerosis (MS).
Forexyard

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Sanofi Pitched $71 Offer to Genzyme Mylan Completes $550 Million Acquisition of Bioniche Pharma Lonza Signs Production Deal With Glaxo Onyx Pharma Gets Japanese Drug Development Deal

Home
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.